
    
      The trial was terminated prematurely on November 1, 2016, due to the emerging clinical
      profile and the evolving treatment and market landscape for lipid-lowering agents. These
      indicated that bococizumab was not likely to provide value to patients, physicians, or
      shareholders. The decision was not based on a recommendation by the independent Data
      Monitoring Committee to stop the program.
    
  